[1]孟召伟,谭建.解读美国甲状腺协会和临床内分泌医师协会2011年甲亢诊治指南[J].国际放射医学核医学杂志,2011,35(4):193-201.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
　MENG Zhao-wei,TAN Jian.Reading and analysis on management guidelines for hyperthyroidism published in 2011 by American Thyroid Association and American Association of Clinical Endocrinologists[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):193-201.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
点击复制

解读美国甲状腺协会和临床内分泌医师协会2011年甲亢诊治指南(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
35
期数:
2011年第4期
页码:
193-201
栏目:
指南解读
出版日期:
1900-01-01

文章信息/Info

Title:
Reading and analysis on management guidelines for hyperthyroidism published in 2011 by American Thyroid Association and American Association of Clinical Endocrinologists
作者:
孟召伟;  谭建
天津医科大学总医院核医学科, 天津 300052
Author(s):
MENG Zhao-wei;  TAN Jian
Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China
关键词:
甲状腺功能亢进症; 碘放射性同位素; 放射疗法; 抗甲状腺药; 甲状腺切除术; 医疗准则
Keywords:
Hyperthyroidism; Iodine radioisotopes; Radiotherapy; Anti thyroid agents; Thyroidectomy; Pactica guideline
DOI:
10.3760/cma.j.issn.1673-4114.2011.04.001
摘要:
最近,美国甲状腺协会和临床内分泌医师协会联合发表了甲亢诊治指南,总共提出了100项指南性的参考建议。该指南系统介绍了甲亢的诊断和治疗,重点强调了131I治疗、抗甲状腺药物治疗和手术治疗的适应证、禁忌证、治疗准备、治疗方法和随诊策略,并详细介绍了儿童甲亢、妊娠期甲亢、甲亢突眼和一些少见甲亢的诊治原则。
Abstract:
Recently, the American Thyroid Association and American Association of Clinical Endocrinologists published "Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists", and created 100 evidence-based recommendations. The guideline systematically introduced the diagnoses and therapies of hyperthyroidism, emphasizing the indications, contraindications, preparations, methodologies and follow-up strategies. The guideline also provided detailed management principles for hyperthyroidism in children and pregnancy. Graves’ ophthalmopathy and some unusual causes of hyperthyroidism.

参考文献/References:

[1] Bahn RS,Burch HB,Cooper DS,et al.Hyperthyroidism and Other Causes of Thyrotoxicosis:Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.Thyroid,2011,21(6):593-646.
[2] Cooper DS,Doherty GM,Haugen BR,et al.Revised American Thyroid Association Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid,2009,19(11):1167-1214.
[3] 孟召伟,谭建.解读美国甲状腺协会2009年甲状腺结节和分化型甲状腺癌诊治指南.国际内分泌代谢杂志,2010,30(5):349-352.

相似文献/References:

[1]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[4]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[5]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[6]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[7]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[8]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[9]杨翠红,刘金剑,褚丽萍,等.125I标记注射用干扰素α2b(假单胞菌)研究雾化吸入与肌肉注射的代谢及组织分布差异[J].国际放射医学核医学杂志,2015,39(3):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
　Yang Cuihong,Liu Jinjian,Chu Liping,et al.Pharmacokinetics and tissue distribution of interferon α2b（Pseudomonas putida）administered via atomization inhalation and intramuscular injection by 125I labeling[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
[10]陈雪梅,周树云,范源,等.表没食子儿茶素没食子酸酯对131I辐射损伤所致甲减大鼠模型抗氧化体系的保护作用[J].国际放射医学核医学杂志,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
　Chen Xuemei,Zhou Shuyun,Fan Yuan,et al.Protection of antioxidant system of EGCG on the thyroid in rat model from 131I radiation damage[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
[11]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[12]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[13]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[14]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[15]王春梅,王雪梅.131I治疗甲亢的现状和研究进展[J].国际放射医学核医学杂志,2010,34(1):31.[doi:10.3760/cma.j.issn.1673-4114.2010.01.008]
　WANG Chun-mei,WANG Xue-mei.The development and current status of 131I treatment for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(4):31.[doi:10.3760/cma.j.issn.1673-4114.2010.01.008]
[16]孙琦婷,赵德善.Graves病甲状腺功能亢进症与血糖代谢[J].国际放射医学核医学杂志,2010,34(3):143.
　SUN Qi-ting,ZHAO De-shan.Graves disease hyperthyroidism and glycometabolism[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(4):143.
[17]冯菲,赵德善.131I治疗青少年儿童甲状腺功能亢进症[J].国际放射医学核医学杂志,2009,33(3):171.[doi:10.3760/cma.j.issn.1673-4114.2009.03.011]
　FENG Fei,ZHAO De-shan.The treatment of hyperthyroidism in adolescents and children with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(4):171.[doi:10.3760/cma.j.issn.1673-4114.2009.03.011]
[18]汤建林,李玉莹,高柳艳,等.甲状腺功能亢进症治疗方法的比较和选择[J].国际放射医学核医学杂志,2009,33(3):175.[doi:10.3760/cma.j.issn.1673-4114.2009.03.012]
　TANG Jian-lin,LI Yu-ying,GAO Liu-yan,et al.The methods and options of the treatment for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(4):175.[doi:10.3760/cma.j.issn.1673-4114.2009.03.012]
[19]潘香颖,李慧贞.甲状腺功能亢进症伴肝功能受损的131I治疗疗效[J].国际放射医学核医学杂志,2009,33(3):179.[doi:10.3760/cma.j.issn.1673-4114.2009.03.013]
[20]王长修.甲状腺功能亢进症患者再次131I治疗的给药剂量对比研究[J].国际放射医学核医学杂志,2009,33(3):182.[doi:10.3760/cma.j.issn.1673-4114.2009.03.016]

备注/Memo

备注/Memo:
收稿日期:2011-05-23。
基金项目:国家自然科学基金(30900376);天津市科委应用基础与前沿技术研究计划重点项目(10JCZDJC19000)
通讯作者:谭建(Email:tanpost@163.com)
更新日期/Last Update: 1900-01-01